Exelixis Inc Prepaid Expense and Other Assets, Current
Exelixis Inc (EXEL) had Prepaid Expense and Other Assets, Current of $60.49 million as of 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-05
- 2026-07-03: Prepaid Expense and Other Assets, Current $60.49M.
- 2026-04-03: Prepaid Expense and Other Assets, Current $75.88M.
- 2026-01-02: Prepaid Expense and Other Assets, Current $75.60M.
- 2025-10-03: Prepaid Expense and Other Assets, Current $76.59M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-07-03 | $60.49M 10-Q · filed 2026-08-05 | |
| 2026-04-03 | $75.88M 10-Q · filed 2026-05-05 | |
| 2026-01-02 | $75.60M 10-Q · filed 2026-08-05 | |
| 2025-10-03 | $76.59M 10-Q · filed 2025-11-04 | |
| 2025-07-04 | $73.83M 10-Q · filed 2025-07-28 | |
| 2025-04-04 | $58.70M 10-Q · filed 2025-05-13 | |
| 2025-01-03 | $68.48M 10-K · filed 2026-02-10 | |
| 2024-09-27 | $69.84M 10-Q · filed 2024-10-29 | |
| 2024-06-28 | $58.25M 10-Q · filed 2024-08-06 | |
| 2024-03-29 | $67.49M 10-Q · filed 2024-04-30 | |
| 2023-12-29 | $67.93M 10-K · filed 2025-02-11 | |
| 2023-09-29 | $66.89M 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $62.26M 10-Q · filed 2023-08-01 | |
| 2023-03-31 | $60.65M 10-Q · filed 2023-05-09 | |
| 2022-12-30 | $62.21M 10-K · filed 2024-02-06 | |
| 2022-09-30 | $52.90M 10-Q · filed 2022-11-01 | |
| 2022-07-01 | $48.28M 10-Q · filed 2022-08-09 | |
| 2022-04-01 | $53.33M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $57.53M 10-K · filed 2023-02-07 | |
| 2021-10-01 | $51.56M 10-Q · filed 2021-11-02 | |
| 2021-07-02 | $49.88M 10-Q · filed 2021-08-05 | |
| 2021-04-02 | $46.34M 10-Q · filed 2021-05-06 | |
| 2021-01-01 | $57.01M 10-K · filed 2022-02-18 | |
| 2020-10-02 | $34.47M 10-Q · filed 2020-11-05 | |
| 2020-07-03 | $43.94M 10-Q · filed 2020-08-06 | |
| 2020-04-03 | $29.77M 10-Q · filed 2020-05-05 | |
| 2020-01-03 | $26.99M 10-K · filed 2021-02-11 | |
| 2019-09-27 | $14.49M 10-Q · filed 2019-10-30 | |
| 2019-06-28 | $12.85M 10-Q · filed 2019-07-31 | |
| 2019-03-29 | $14.15M 10-Q · filed 2019-05-01 | |
| 2018-12-28 | $31.07M 10-K · filed 2020-02-25 | $15.02M 10-K · filed 2019-02-22 |
| 2018-09-28 | $12.28M 10-Q · filed 2018-11-01 | |
| 2018-06-29 | $10.33M 10-Q · filed 2018-08-01 | |
| 2018-03-30 | $6.85M 10-Q · filed 2018-05-02 | |
| 2017-12-29 | $8.75M 10-K · filed 2019-02-22 | |
| 2017-09-30 | $8.01M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $4.43M 10-Q · filed 2017-08-02 | |
| 2017-03-31 | $6.30M 10-Q · filed 2017-05-01 | |
| 2016-12-31 | $5.42M 10-Q · filed 2017-11-01 | |
| 2016-12-30 | $5.42M 10-K · filed 2018-02-26 | |
| 2016-09-30 | $7.15M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $4.66M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $4.79M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $3.81M 10-K · filed 2017-02-27 | |
| 2015-09-30 | $3.95M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $2.73M 10-Q · filed 2015-08-11 | |
| 2015-03-31 | $5.21M 10-Q · filed 2015-04-30 | |
| 2014-12-31 | $3.48M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $7.86M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $4.79M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $5.39M 10-Q · filed 2014-05-01 | |
| 2013-12-31 | $5.11M 10-K · filed 2015-03-02 | |
| 2013-09-30 | $7.80M 10-Q · filed 2013-10-30 | |
| 2013-06-30 | $5.88M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $11.03M 10-Q · filed 2013-05-07 | |
| 2012-12-31 | $6.10M 10-K · filed 2014-02-20 | |
| 2012-09-30 | $6.10M 10-Q · filed 2012-11-07 | |
| 2012-06-30 | $4.50M 10-Q · filed 2012-08-02 | |
| 2012-03-31 | $4.64M 10-Q · filed 2012-05-03 | |
| 2011-12-31 | $4.37M 10-K · filed 2013-02-21 | |
| 2010-12-31 | $14.93M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |